<DOC>
	<DOCNO>NCT02664194</DOCNO>
	<brief_summary>To evaluate improve safety efficacy hypothermia adjunctive therapy percutaneous coronary intervention patient acute myocardial infarction .</brief_summary>
	<brief_title>Hypothermia Adjunctive Therapy Percutaneous Intervention Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>Single-center , prospective , randomize , control clinical study involve least 70 patient 10 roll-in patient ( train purpose ) . Male female adult present acute myocardial infarction may eligible research study . To qualify , patient must go Emergency Room within 6 hour onset chest pain , present anterior inferior acute myocardial infarction elevation ST segment great 1mm 2 contiguous lead anterior inferior wall eligible performance percutaneous intervention procedure . The intervention intravascular hypothermia use Proteus System® adjunctive method percutaneous coronary intervention , adjunct hypothermia method parameter . During randomization phase , least 70 patient meet eligibility criterion randomly assign 03 hour hypothermia group ( percutaneous coronary intervention + cooling ) , 01 hour hypothermia group ( percutaneous coronary intervention + cool ) control group ( percutaneous coronary intervention ) 1:1:1 ratio . All patient receive PCI + Cooling also randomize group A B . Group A receive 1 liter chill normal saline ( 4°C ) prior PCI/reperfusion , Group B receive chill normal saline ( 4°C ) , prior PCI . All patient include randomization phase include statistical analysis . Approximately 10 Roll-in patient may enrol center ( train purpose ) , anterior inferior wall infarct . The primary endpoint reduction infarct size ( % LV ) , study cardiac magnetic resonance imaging ( cMR ) use late gadolinium enhancement 5 day AMI , 30 day infarction . The secundary endpoint - incidence major adverse cardiac event ( MACE ) death within 30 day ; - resolution ST segment elevation PCI ; - ejection fraction determine cMR 30 day . - evaluation adverse event potentially relate hypothermia and/or endovascular cooling within 30 day . - Differences plaquelet aggregation cool rewarming .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<criteria>Patient age &gt; 18 year . The patient must symptoms consistent acute myocardial infarction ( chest pain , , pain arm , etc . ) improve nitroglycerin , onset symptom great 30 minute less six hour admission emergency room . RollIn Patients : Anterior Inferior MI STsegment elevation &gt; 1mm two contiguous anterior precordial inferior lead . Randomized Patients : Anterior wall AMI elevation ST segment &gt; 1mm two anterior precordial contiguous lead . Patient must eligible PCI . The patient patient 's legal guardian agree willing sign inform consent form participate clinical study ( country appropriate ) . The patient previous myocardial infarction . The patient experience cardiogenic shock ( systolic blood pressure ( SBP ) &lt; 80 mmHg responsive fluid , SBP &lt; 100 mmHg vasopressor , need intraaortic balloon IAB ) . The patient presenting resuscitate cardiac arrest , atrial fibrillation Killip risk Stratification class II IV . The patient aortic dissection require immediate surgical procedural intervention PCI . The patient know Congestive Heart Failure ( CHF ) , hepatic failure , endstage kidney disease sever renal failure ( clearance &lt; 30 ml/min/1.73m2 . The patient febrile ( temperature &gt; 37.5 ° ) experience infection fever last 5 day . The patient know previous CABG . The patient know recent stroke within 90 day admission . Cardiopulmonsary decompensation occur en route hospital opinion physician imminent likely occur follow presentation clinical site . Contraindications hypothermia , patient know hematologic dyscrasia affect thrombosis 9e.g. , cryoglobulinemia , sickle cell disease , serum cold agglutinin ) vasospastic disorder ( Raynaud 's thromboangitis obliterans . The patient know hypersensitivity contraindication aspirin , heparin , sensitivity contrast [ agent ] , adequately premedicated . The patient known history bleed diathesis , coagulopathy , cryoglobulinemia sickle cell anemia , refuse blood transfusion . The patient &lt; 1.5 ( 4 foot 11 inch ) tall . The patient know hypersensitivity buspirone hydrochloride meperidine and/or treat monoamine oxidase inhibitor last 14 day . The patient known history severe hepatic renal failure , untreated hypothyroidism , Addison 's disease , benign prostatic hypertrophy urethral stricture , opinion physician , would incompatible administration pethidine/meperidine . The patient Inferior Vena Cava filter place ( IVC ) . The patient preMI life expectancy &lt; 1 year due underlie medical condition preexist morbidity . The patient know , unresolved history drug use alcohol dependency , able comprehend follow instruction . The patient currently enrol another investigational drug device trial complete primary endpoint . ( Note : For purpose protocol , patient involve extended followup trial product investigational currently commercially available consider enrol investigational trial ) . The patient apprehensive unwilling undergo require MRI image followup , document suspected diagnosis claustrophobia , Gadolinium allergy , permanent Atrial Fibrillation . The patient receive thrombolytic therapy en route hospital The patient show clinical evidence spontaneous reperfusion observe symptomatically and/ ECG finding ( partial complete ST resolution ECG randomization ) upon admission The patient vulnerable subject , instance , person detention ( i.e. , prisoner ward state ) The patient female know pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hypothermia</keyword>
	<keyword>Rewarming</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Percutaneous Cornonary Intervention</keyword>
</DOC>